Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904492 | 0.91 | ADRB1 (0.55) | ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL12378394 | 0.88 | MAPT (0.45) | ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL14015983 | 0.84 | ADRB1 (0.48) | ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL12378451 | 0.82 | ADRB1 (0.55) | ADRB1HTR2AHTR2BSIGMAR1ADRA1A | |
| SCHEMBL904556 | 0.82 | ADRB1 (0.55) | ADRB1HTR2AHTR2BSIGMAR1ADRA1A | |
| SCHEMBL12378435 | 0.82 | ADRB1 (0.55) | ADRB1HTR2AHTR2BSIGMAR1ADRA1A | |
| SCHEMBL2291016 | 0.81 | ADRB1 (0.58) | ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL3411478 | 0.79 | ADRB1 (0.70) | ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL2115763 | 0.79 | ADRB1 (0.70) | ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL2116100 | 0.78 | ADRB1 (0.50) | ADRB1HTR2AHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243352-A1 | METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-28 | — | — | US | disclosed |
| US-20140243352-A1 | METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243352-A1 | METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS | LIPG, DPP7, IAPP | ADRB1 491/4885HTR2A 1027/4885HTR2B 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.